KROS - Keros Therapeutics Inc - Stock & Dividends

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative treatments for patients with disorders related to dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins.

The company's lead product candidate, KER-050, is being developed to treat low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. These conditions can lead to severe fatigue, weakness, and increased risk of infections and bleeding.

In addition to KER-050, Keros Therapeutics is also developing KER-012, which is currently in Phase II clinical trials for the treatment of pulmonary arterial hypertension and cardiovascular disorders. Pulmonary arterial hypertension is a rare and debilitating condition characterized by high blood pressure in the lungs, leading to shortness of breath, fatigue, and limited exercise capacity.

The company is also investigating KER-065, which is in Phase I clinical trials for the treatment of obesity and neuromuscular diseases. Obesity is a major public health concern, and neuromuscular diseases, such as muscular dystrophy, can significantly impact quality of life.

Keros Therapeutics has established a collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. This partnership aims to accelerate the development and availability of KER-050 for patients in need.

Founded in 2015, Keros Therapeutics is headquartered in Lexington, Massachusetts, and is committed to advancing its pipeline of novel therapeutics to improve the lives of patients with serious diseases. For more information, visit their website at https://www.kerostx.com.